Pressmeddelande

BioStock: Biosergen’s CEO: “I’m optimistic that we may cure patients”

Cision Publicerad: 06 Nov 11:05

Biosergen recently announced the completion of treatment for the first cohort of patients in its proof-of-concept trial for its antifungal drug candidate BSG005. Most patients improved significantly, reflecting BSG005’s potential as a life-saving therapy. The next step involves dose escalation for the upcoming cohort. Importantly, between November 18 and 29, shareholders can exercise the warrants TO3, which could add a maximum of approximately SEK 45 million to the company, funding it well through 2025.

Read the interview with CEO Tine Olesen at biostock.se:

https://www.biostock.se/en/2024/11/biosergens-ceo-im-optimistic-that-we-may-cure-patients/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Nyheter om Biosergen

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!